Clik here to view.
Monday Biotech Deal Review: June 28, 2010
We follow a number of trends here at the blog, and two of them showed up as Canadian deals this week. Add those to the Biovail-Valeant merger, Æterna’s offering and a whole slew of commercial deals,...
View ArticleClik here to view.
Monday Biotech Deal Review: September 27, 2010
Welcome to your Monday Biotech Deal Review. I am very excited to be writing for The Cross-Border Biotech Blog after working with Jeremy behind the scenes over the past three years. [ed. welcome (back)...
View ArticleClik here to view.
Monday Biotech Deal Review: October 4, 2010
This week’s Monday Deal Review brings you the usual assortment of biotech wheelings and dealings from the past week, including a summary of the newly completed Valeant / Biovail merger. M&Eh The...
View ArticleClik here to view.
Q3 Canadian Healthcare Review – Weakness Continues BUT Some Bright Spots
Data in the Q3 2010 Canadian Healthcare Review from the Equicom Group (co-authored by James Smith, Vice President Healthcare at Equicom and myself) shows a continuation of the weakness in biotech...
View ArticleClik here to view.
Biotech Trends Update — IP Constituencies: Innovator-Generic Mixing Continues...
As traditional pharma companies continue to diversify their revenue sources in the face of their pending patent cliffs, we have followed their entry into and expansion of their generics business lines....
View ArticleClik here to view.
Monday Deal Review: April 29, 2013
Welcome to your Monday Biotech Deal Review for April 29, 2013! This week saw Ergoresearch and Amorfix close their previously announced private offerings. Trimel, meanwhile, has raised $40 million from...
View ArticleClik here to view.
Monday Deal Review: June 3, 2013
Welcome to your Monday Biotech Deal Review for June 3, 2013! The past week’s major news was Valeant’s major acquisition of Bausch + Lomb for a combined debt and equity amount of $8.7 billion,...
View ArticleClik here to view.
Monday Deal Review: June 24, 2013
Welcome to your Monday Biotech Deal Review for June 24, 2013! The past weeks’ big news is Antibe’s IPO, which resulted in approximately $2.1 million in proceeds. Antibe also concurrently made a private...
View ArticleClik here to view.
Monday Deal Review: July 8, 2013
Welcome to your Monday Biotech Deal Review for July 8, 2013! A busy two weeks has seen lot of activity on the debt financing side of things. This includes Paladin and Bioniche’s complex debt financing...
View Article
